Epiheart develops cardiac cell therapy administered during cardiac surgery to treat heart failure. The company focuses on Cardiac Micrograft Therapy™, which aims to improve ventricular wall structure and reduce scar size in patients. They are currently conducting clinical studies and seeking collaborations for surgical administration of advanced cell therapies.
Funding
$760K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Patients with heart failure often experience irreparable damage to the heart muscle due to ischemic heart diseases and heart attacks, leading to reduced long-term survival rates and diminished quality of life. Current treatments, such as drugs, catheterization, stenting, and coronary artery bypass graft (CABG) surgery, primarily address blockages in coronary arteries but do not effectively repair tissue damage or scarring of the heart muscle.
Solution
EpiHeart provides medical devices and procedural solutions to enable Cardiac Micrograft Therapy™, a regenerative treatment administered during cardiac surgery to address damaged heart tissue. The therapy utilizes the patient’s own cardiac tissue, processed into micrografts, and positioned on top of the damaged area in the heart muscle. This approach supplements CABG surgery with minimal impact on the duration or risks, and pre-clinical and clinical results indicate positive effects on ventricular wall structure and scar size, critical factors contributing to heart failure.
Target Audience
The primary customers are cardiac surgeons and hospitals performing CABG or LVAD surgery seeking to improve long-term survival and quality of life for heart failure patients through advanced cell therapies.
Features
- CE-marked devices specifically designed for operating room use, ensuring a small footprint and flexible positioning
- Cooling Plate device to maintain optimal cell conditions during tissue transplant assembly
- Procedure package with sterilized medical devices ready for each surgery
- Operating Room Centrifuge (ORC-40) for rinsing autologous tissue micrografts, featuring a compact design (20 kg) and compatibility with standard 50mL centrifuge tubes via a sterile adapter
- Multi-purpose centrifuge adapters for diverse applications in cell and tissue sample processing
- Comprehensive documentation and training for treatment protocols and best practices